Heart Failure, Sleep Disordered Breathing
Conditions
Keywords
CARDIAC REHABILITATION, Nocturnal Ventilation, Apnea hypopnea index is > 15/h
Brief summary
Sleep disordered breathing (SDB) is a frequent comorbidity for heart failure patients. Its prevalence varies according to the seriousness of the condition of the patients, but it is present in approximately 50% of patients. Screening patients for SDB and managing them by providing adapted ventilation therapy should improve their quality of life or even their prognosis. Moreover, SDB lowers nocturnal cardiovascular recovery abilities and leads to an increase in fatigability and, as a result, exercise intolerance in patients with heart failure. Physical training as part of a cardiac rehabilitation programme provides many benefits, including improving patients' exercise capacities. Our hypothesis is that adapted sleep disordered breathing therapy during rehabilitation will lead to an improvement in rehabilitation results.
Detailed description
Controlled, randomised, multicentre study. Patients will be assessed prior to starting the rehabilitation programme with regard to exercise tolerance parameters (cardiopulmonary exercise test, 6 minute walk test), ultrasound parameters and biological parameters (Na, Hb, BNP). The cardiac rehabilitation programme will include education, secondary prevention and physical training components in each of the two groups. The physical training component will include a minimal base of activities that is identical for both groups. The nocturnal therapy device will be adapted to the type of SDB specific to each patient (central, mixed, obstructive). The randomisation will be stratified by centre according to predictive factors for performance improvement during rehabilitation. The main objective is to evaluate the improvement in physical performance resulting from adapted ventilation on SDB compared to physical training alone in patients with heart failure.
Interventions
OTHERventilation therapy
The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications. There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings. Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient.
Sponsors
ResMed
ResMed Foundation
Adep Assistance
French Cardiology Society
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have NYHA class II to IIIb heart failure, operated or not, ischemic or not, without significant valve pathology. * Referred to cardiac rehabilitation * With an EF \< 40% * And an apnea-hypopnea index \> 15/h (determined by a nasal flow recording method) * Have signed the consent document to participate in the study.
Exclusion criteria
* Patients who have been stabilised for less than 10 days (inotropic drugs or modification of the anticipated resynchronisation or PM parameters) * Patients who already use sleep disordered breathing devices * Resting SBP \< 80 mmHg (averaged over 3 separate measurements) * Recent angioplasty (within the last 10 days) * Infarction within the last 10 days * Heart surgery within the last 15 days * Valve dysfunction requiring surgery * Uncontrolled high blood pressure (BP \> 180 and/or 110 mmHg) * Anaemia (Hb \< 9g/dl) * Haemodialysis * Patient receiving circulatory assistance * Severe chronic respiratory failure (FEV1 \< 1000) or hypercapnia greater than 46 mmHg * Patient incapable of performing a 6 minute walk test and an exercise test * Absolute contraindication for an exercise test and/or physical training according to the recommendations of the French Society of Cardiology * Evolving myopericarditis * Severe ventricular rhythm disorders that do not stabilise with treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak VO2 | Day 1 | The primary endpoint is the relative improvement of exercise tolerance, estimated using the changes in the patient's peak VO2 measured before starting and after finishing the rehabilitation programme between the both group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Physical training compliance | between 4 and 9 weeks | Secondary endpoints include compliance with rehabilitation sessions, estimated by comparing the number of sessions in which training was effectively carried out with the anticipated number of sessions and other exercise tolerance parameters (maximum power, duration of exercise, submaximal parameters) in each group. |
Countries
France
Outcome results
None listed